Search results
Results from the WOW.Com Content Network
The term post-vac (or post-vac syndrome, post-vaccine syndrome, post-vax of long-vax [33]) is used in Germany, Switzerland [34] and Austria [35] in connection with long-standing symptoms somewhat similar to long covid symptoms and does not indicate a defined disease or designation.
The Blueprint listed a Global Target Product Profile (TPP) for COVID‑19, identifying favorable attributes of safe and effective vaccines under two broad categories: "vaccines for the long-term protection of people at higher risk of COVID‑19, such as healthcare workers", and other vaccines to provide rapid-response immunity for new outbreaks ...
The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, [2] [33] is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials , logistics, and manufacturing.
The goals of the project – to develop, manufacture, and distribute hundreds of millions of COVID-19 vaccine doses by the end of 2020 – were initially criticized as being unrealistic, based on decades of experience in developing viral infection vaccines which normally require years or decades for assuring the chosen vaccine will not be toxic ...
COVID-19 vaccine production by country Country Doses (millions) 3 Mar 2021 [1] 31 Jan 2022 [2] China 141.6: 4951.4 European Union 81.0:
The unlisted biotech firm CureVac will become the second company to launch human trials of an experimental coronavirus vaccine in Germany, two people familiar with the plans told Reuters on Tuesday.
Beyond CVnCoV, CureVac has also partnered with GlaxoSmithKline (GSK) to develop a new generation of mRNA-based COVID-19 vaccines. Human testing is due in late 2021. [40] [needs update] The start of the phase 1 study with the product candidate CV2CoV, which was announced for the fourth quarter of 2021, had to be postponed to the first quarter of ...
The CHMP's decision to start the rolling review is based on preliminary results from laboratory studies (non-clinical data) and early clinical studies in adults, which suggest that the vaccine triggers the production of antibodies that target SARS-CoV-2, the virus that causes COVID-19, and may help protect against the disease. [24]